MacroGenics traded at $6.49 this Monday November 28th, increasing $0.57 or 9.63 percent since the previous trading session. Looking back, over the last four weeks, MacroGenics gained 26.76 percent. Over the last 12 months, its price fell by 63.76 percent. Looking ahead, we forecast MacroGenics to be priced at 5.73 by the end of this quarter and at 5.18 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Daiichi Sankyo 4,536.00 -26.00 -0.57% 60.59%
AbbVie 158.43 -1.19 -0.75% 35.54%
Amgen 282.62 -1.12 -0.39% 38.90%
AstraZeneca 11,084.00 34.00 0.31% 33.93%
Biogen 291.90 -13.25 -4.34% 23.63%
Bristol-Myers Squibb 79.14 -0.10 -0.13% 44.84%
Genmab 3,211.00 -22.00 -0.68% 26.52%
Geron 2.29 0.07 3.15% 57.93%
Gilead Sciences 85.21 -1.05 -1.22% 20.61%
Immunogen 5.08 -0.07 -1.36% 6.95%
J&J 177.33 0.09 0.05% 11.00%
Karyopharm Therapeutics 4.89 -0.05 -1.01% -28.61%
Eli Lilly 365.77 0.52 0.14% 47.46%
MacroGenics 6.49 0.57 9.63% -63.76%
Merck & Co 108.45 0.95 0.88% 44.81%
Mirati Therapeutics 95.67 -2.95 -2.99% -29.65%
Puma Biotechnology 4.41 0.15 3.52% 43.18%
Pfizer 49.57 0.36 0.73% -5.40%
Regeneron Pharmaceuticals 741.48 5.25 0.71% 16.49%
Roche Holding 311.05 -1.35 -0.43% -13.51%
Seattle Genetics 121.22 -2.22 -1.80% -26.67%
Xencor 28.17 -0.37 -1.30% -21.95%

Indexes Price Day Year
USND 11049 -176.86 -1.58% -29.99%
US2000 1831 -38.23 -2.05% -18.33%

MacroGenics
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.